Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
BMJ Open ; 9(9): e031356, 2019 09 12.
Artigo em Inglês | MEDLINE | ID: mdl-31515433

RESUMO

OBJECTIVE: The aim of the analysis is to assess the organisational and economic consequences of adopting an early discharge strategy for the treatment of acute bacterial skin and skin structure infection (ABSSSI) and osteomyelitis within infectious disease departments. SETTING: Infectious disease departments in Greece, Italy and Spain. PARTICIPANTS: No patients were involved in the analysis performed. INTERVENTIONS: An analytic framework was developed to consider two alternative scenarios: standard hospitalisation care or an early discharge strategy for patients hospitalised due to ABSSSI and osteomyelitis, from the perspective of the National Health Services of Greece, Italy and Spain. The variables considered were: the number of annual hospitalisations eligible for early discharge, the antibiotic treatments considered (ie, oral antibiotics and intravenous long-acting antibiotics), diagnosis-related group (DRG) reimbursements, number of days of hospitalisation, incidence and costs of hospital-acquired infections, additional follow-up visits and intravenous administrations. Data were based on published literature and expert opinions. PRIMARY AND SECONDARY OUTCOME MEASURES: Number of days of hospitalisation avoided and direct medical costs avoided. RESULTS: The total number of days of hospitalisation avoided on a yearly basis would be between 2216 and 5595 in Greece (-8/-21 hospital beds), between 15 848 and 38 444 in Italy (-57/-135 hospital beds) and between 7529 and 23 520 in Spain (-27/-85 hospital beds). From an economic perspective, the impact of the early discharge scenario is a reduction between €45 036 and €149 552 in Greece, a reduction between €182 132 and €437 990 in Italy and a reduction between €292 284 and €884 035 in Spain. CONCLUSIONS: The early discharge strategy presented would have a positive organisational impact on National Health Services, leading to potential savings in beds, and to a reduction of hospital-acquired infections and costs.


Assuntos
Antibacterianos , Procedimentos Clínicos , Infecção Hospitalar/prevenção & controle , Hospitalização , Osteomielite , Dermatopatias Bacterianas , Antibacterianos/economia , Antibacterianos/uso terapêutico , Redução de Custos , Procedimentos Clínicos/economia , Procedimentos Clínicos/organização & administração , Grécia/epidemiologia , Departamentos Hospitalares/métodos , Hospitalização/economia , Hospitalização/estatística & dados numéricos , Humanos , Incidência , Itália/epidemiologia , Osteomielite/economia , Osteomielite/epidemiologia , Osteomielite/terapia , Discrepância de GDH , Alta do Paciente , Dermatopatias Bacterianas/economia , Dermatopatias Bacterianas/epidemiologia , Dermatopatias Bacterianas/terapia , Espanha/epidemiologia , Estatística como Assunto
2.
Hum Vaccin Immunother ; 15(2): 295-304, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30111224

RESUMO

INTRODUCTION: Vaccination against various pathogens is recommended for HIV positive adults. There are not sufficient data either on vaccination coverage of HIV positive adults or the risk factors associated with poor adherence to routine vaccination. PATIENTS-METHODS: During the period 2004-2014 vaccination coverage of a group of HIV infected adults against hepatitis A virus (HAV), hepatitis B virus (HBV), seasonal influenza virus and pneumococcal disease was recorded. Vaccination coverage was separated into two chronological periods, before and after 2010, as 2010 marks the start of the economic crisis in Greece. RESULTS: 1210 patients were included in our study. Vaccine coverage throughout the study for hepatitis B, hepatitis A, seasonal influenza and pneumococcal infection was 73.6%, 70.4%, 39% and 79%, respectively. The complete lack of insurance coverage was an independent factor of non-compliance in all proposed vaccines (vaccination against pneumococcal disease: OR: 0.82 95%CI: 0.49-1.35, vaccination against HBV: OR: 0.82, 95% CI: 0.45-1.49, vaccination against HAV OR: 0.54, 95%CI: 0.34-0.87, vaccination against influenza: OR: 1.27, 95% CI: 0.76-2.10). In addition, low educational level was associated with poor compliance to vaccination against pneumococcal disease, hepatitis A, hepatitis B, and influenza. Finally, the recommendation for vaccination after the onset of the economic crisis (2010) led to poor compliance to vaccination against HBV, HAV and pneumococcal disease, but not against influenza. CONCLUSIONS: In our study, vaccination coverage for vaccine-preventable diseases was found to be insufficient for HIV positive adults in Northern Greece. Also, low educational level, lack of insurance coverage and economic distress have contributed to poor vaccine compliance, leading to poor protection of the HIV positive population and decreased immune coverage in the community.


Assuntos
Infecções por HIV/complicações , Hepatite B/prevenção & controle , Influenza Humana/prevenção & controle , Cooperação do Paciente , Infecções Pneumocócicas/prevenção & controle , Vacinação/psicologia , Adolescente , Adulto , Idoso , Feminino , Grécia , Humanos , Cobertura do Seguro , Masculino , Pessoa de Meia-Idade , Cobertura Vacinal , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA